DCM
RXII

DAFNA Capital Management’s GALENA BIOPHARMA INC COM RXII Stock Holding History

DAFNA Capital Management’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-250,000
Closed -$348K – 92
2015
Q1 		$348K Buy
+250,000
New +$348K 0.27% 55
2013
Q4 		– Sell
-375,000
Closed -$855K – 57
2013
Q3 		$855K Buy
+375,000
New +$855K 0.93% 26

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DAFNA Capital Management's RXII Position: Q2 2015 in Review

DAFNA Capital Management sold out of GALENA BIOPHARMA INC COM (RXII) in Q2 2015, closing a stake of 250,000 shares — an estimated $348K sold.

DAFNA Capital Management first reported a position in RXII in Q3 2013 and held it in 2 quarters. The position peaked at $855K in Q3 2013. 86 funds tracked by Wall St. Rank hold RXII as of Q2 2015.

  • DAFNA Capital Management reported no remaining GALENA BIOPHARMA INC COM position as of Q2 2015 after selling out during the quarter.
  • DAFNA Capital Management sold 250,000 GALENA BIOPHARMA INC COM shares in Q2 2015, an estimated $348K.
  • DAFNA Capital Management first reported a position in GALENA BIOPHARMA INC COM in Q3 2013 and held it in 2 quarters.
  • DAFNA Capital Management's GALENA BIOPHARMA INC COM position peaked at $855K in Q3 2013.
  • 86 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q2 2015.

Based on DAFNA Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.